Global Array Instruments Market Expected to Reach USD 11.9 Billion by 2031 as Demand Increases in Research and Clinical

Zoom into the future of microscopy with our comprehensive Array Instruments Market research report. Explore industry trends, technological advancements, key players, and market dynamics

[Boston, 4th June 2025] – Clearview Market Insights (CVMI) projects that the global array instruments market will more than double from USD 5.4 billion in 2024 to USD 11.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 12.1 percent. This growth is driven by increasing demand for personalized medicine, multiplexed diagnostic platforms, and high-throughput drug screening tools across both developed and emerging economies.

“Array-based technologies are evolving from basic gene expression tools into powerful multi-omics platforms that integrate genomic, transcriptomic, and proteomic data for precision diagnostics and therapeutics,” said Dr. Mira Patel, genomics innovation lead at CVMI. “This shift is unlocking transformative potential in oncology, neurology, rare disease research, and even agricultural applications.”

Request Sample @ https://clearviewmarketinsights.com/report-details/global-array-instruments-market/

Key Numbers

  • 2024 Market Value: USD 5.4 billion
  • 2031 Market Value: USD 11.9 billion
  • Seven-Year CAGR: 12.1 percent
  • DNA Arrays Share (2024): 38%
  • North America Share: 42%, Asia-Pacific fastest-growing region

Market Drivers

  • Precision medicine and population-scale screening
  • Expansion of biomarker discovery programs
  • Multi-omics platform integration
  • Technological miniaturization and AI analytics
  • Increased funding from NIH, Horizon Europe, and Asian genomics initiatives

Company Highlights

  • Agilent launched high-density rare-variant arrays for translational genomics.
  • Illumina deepened partnerships with government-funded genetic screening projects.
  • Thermo Fisher connected proteomic array data to cloud analytics suites for clinical trials.
  • Arrayit brought DTC testing kits for protein biomarkers to the consumer market.
  • Bio-Rad introduced ELISA-array hybrids for autoimmune disease detection.

Regional Highlights

  • North America: Sustained investment in genomics infrastructure, academic trials, and diagnostic innovation.
  • Asia-Pacific: Government-led genome sequencing initiatives drive rapid adoption.
  • Europe: IVDR compliance spurs demand for certified clinical-grade array systems.
  • LATAM & MEA: Market expansion supported by public-private genomics collaborations and global health donors.

2024–2025 Milestones

Quarter

Event

Outcome

Q1 2024

Agilent launches G3 HD arrays

Enables 50% higher resolution gene expression profiling

Q2 2024

Thermo Fisher integrates array data into oncology cloud suite

Accelerates patient stratification in trials

Q3 2024

Illumina signs regional genomics pact in Southeast Asia

Adds 5 million samples to population genomics pipeline

Q1 2025

Bio-Rad introduces dual-modality ELISA-array systems

Improves throughput in autoimmune diagnostics

 

 

 

 

 

For more insights, visit https://clearviewmarketinsights.com/

 

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

 

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369


Frooti 123

158 Blog mga post

Mga komento